Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | ACACB | O00763 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | HTR7 | P34969 | 2/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | CCR3 | P51677 | 2/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7508133 | 0.83 | HSD17B10 (0.48) | MEN1LMNAKMT2AACACBHRH3 | |
| SCHEMBL10607203 | 0.81 | HRH3 (0.60) | MEN1KMT2AHRH3SIGMAR1 | |
| Hydrochloric Acid SCHEMBL10608924 | 0.80 | GAA (0.61) | MEN1KMT2AHRH3SIGMAR1 | |
| SCHEMBL7508127 | 0.79 | DRD2 (0.48) | MEN1LMNAKMT2AACACBEPHX2 | |
| SCHEMBL2056241 | 0.78 | HRH3 (0.68) | MEN1LMNAKMT2ASLC6A4SLC6A2 | |
| SCHEMBL20788247 | 0.77 | HTR2C (0.58) | SLC6A4SLC6A2SLC6A3ACACBHRH3 | |
| SCHEMBL17848470 | 0.77 | HTR2C (0.58) | SLC6A4SLC6A2SLC6A3ACACBHRH3 | |
| SCHEMBL10261843 | 0.77 | HTR2C (0.58) | SLC6A4SLC6A2SLC6A3ACACBHRH3 | |
| SCHEMBL5394839 | 0.76 | HRH3 (0.54) | MEN1LMNAKMT2ASLC6A4SLC6A2 | |
| SCHEMBL13703558 | 0.76 | LTA4H (0.54) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6951874-B2 | Compounds | ASTRAZENECA AB (SE) | 2005-10-04 | — | — | US | disclosed |
| US-6943188-B2 | Hydroxyalkyl compounds | ASTRAZENECA AB (SE) | 2005-09-13 | — | — | US | disclosed |
| US-6927222-B2 | 1,3,4,5-tetrahydro-pyrido(4,3-b)indole-2-yl derivative useful for treating rheumatoid arthritis, chronic obstructive pulmonary disease, asthma and multple sclerosis | ASTRAZENECA AB (SE) | 2005-08-09 | — | — | US | disclosed |
| EP-1263724-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2005-05-18 | — | — | EP | disclosed |
| US-20030158225-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2003-08-21 | — | — | US | disclosed |
| US-20030149047-A1 | Novel compounds | ASTRAZENCA AB (SE) | 2003-08-07 | — | — | US | disclosed |
| US-20030144267-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158225-A1 | Novel compounds | UGT2B7, RPS4Y1, RPS4X | MEN1 1294/4885LMNA 3735/4885KMT2A 3277/4885 |
| US-20030149047-A1 | Novel compounds | RPS4Y1, RPS4X, RPS6 | MEN1 1120/4885LMNA 3811/4885KMT2A 3481/4885 |
| US-20030144267-A1 | Novel compounds | RPS4X, RPS4Y1, UGT2B7 | MEN1 1455/4885LMNA 3715/4885KMT2A 3037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.